WHO cautions against overestimating AI’s impact on healthArtificial intelligence (AI) has the potential to improve the delivery of healthcare, but only if ethics and human Share XWHO cautions against overestimating AI’s impact on healthhttps://pharmaphorum.com/news/who-cautions-against-overestimating-ais-impact-on-health/
Key insights for a successful first-time product launchPre-commercial & Emerging pharma companies may not think they have the resources to match the launch strategies of Share XKey insights for a successful first-time product launchhttps://pharmaphorum.com/sales-marketing/key-insights-for-a-successful-first-time-product-launch/
COVID heralds a faster future for drug development (if stakeholders can collaborate)COVID-19 has been a trial-by-fire showing just how quickly drugs and vaccines can be developed under the right Share XCOVID heralds a faster future for drug development (if stakeholders can collaborate)https://pharmaphorum.com/views-and-analysis/covid-heralds-a-faster-future-for-drug-development-if-stakeholders-can-work-together/
Solving the “information challenge” of rare disease diagnosisGetting a diagnosis is often the biggest challenge facing a rare disease patient in the UK. We take Share XSolving the “information challenge” of rare disease diagnosishttps://deep-dive.pharmaphorum.com/magazine/research-and-development-2021/solving-the-information-challenge-of-rare-disease-diagnosis/
Life sciences must become cloud-first to seize the science of tomorrowIf the power of the life sciences industry to innovate and collaborate were ever in doubt, the speed Share XLife sciences must become cloud-first to seize the science of tomorrowhttps://pharmaphorum.com/views-analysis-digital/life-sciences-must-become-cloud-first-to-seize-the-science-of-tomorrow/
Real-world evidence: breaking boundaries in rare diseaseThe COVID-19 pandemic has added a new layer of complexity to the drug development process. Launch timelines have Share XReal-world evidence: breaking boundaries in rare diseasehttps://pharmaphorum.com/partner-content/real-world-evidence-breaking-boundaries-in-rare-disease/
A collaborative approach to greater diversity in clinical trialsThe need for diversity in clinical trial populations has been a topic of discussion across regulators and the Share XA collaborative approach to greater diversity in clinical trialshttps://deep-dive.pharmaphorum.com/magazine/patients-and-partnerships-2020/a-collaborative-approach-to-greater-diversity-in-clinical-trials/
True patient-focused research through decentralised and hybrid trialsHow can pharma improve the patient-centricity of its trials during COVID-19 and beyond? Experts from across the sector Share XTrue patient-focused research through decentralised and hybrid trialshttps://deep-dive.pharmaphorum.com/magazine/patients-and-partnerships-2020/true-patient-focused-research-through-decentralised-and-hybrid-trials/
Pharma’s digital transformation journey and the role of customer reference dataBetter management of customer data could help pharmaceutical companies’ digital transformation, according to Veeva’s Rebecca Silver. pharmaphorum’s Richard Share XPharma’s digital transformation journey and the role of customer reference datahttps://pharmaphorum.com/views-analysis-digital/pharmas-digital-transformation-journey-and-the-role-of-customer-reference-data/
